{
    "root": "50db6996-9309-4d16-b094-020490ec2539",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Megestrol Acetate",
    "value": "20250325",
    "ingredients": [
        {
            "name": "HYPROMELLOSE 2910 (3 MPA.S)",
            "code": "0VUT3PMY82",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "SODIUM BENZOATE",
            "code": "OJ245FE5EU",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_113455"
        },
        {
            "name": "TRISODIUM CITRATE DIHYDRATE",
            "code": "B22547B95K"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17992"
        },
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "Megestrol Acetate",
            "code": "TJ2M0FR8ES",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_6723"
        }
    ],
    "indications": {
        "text": "megestrol acetate oral suspension indicated treatment anorexia , cachexia , unexplained significant weight loss patients diagnosis acquired immunodeficiency syndrome ( aids ) . limitations therapy megestrol acetate oral suspension weight loss insti\u00adtuted treatable causes weight loss sought addressed . treatable causes include possible malignancies , systemic infections , gastrointestinal disorders affecting absorption , endocrine disease , renal disease psychiatric diseases . megestrol acetate oral suspension intended prophylactic avoid weight loss .",
        "doid_entities": [
            {
                "text": "acquired immunodeficiency syndrome (DOID:635)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_635"
            },
            {
                "text": "immunodeficiency syndrome (DOID:612)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_612"
            },
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "immunodeficiency",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_101997"
            }
        ]
    },
    "contraindications": {
        "text": "obtain negative pregnancy test females reproductive potential prior initiating treatment ( 2.1 ) recommended adult initial megestrol acetate oral suspension 625 mg/day ( 5 ml/day one teaspoon daily ) ( 2.2 ) . shake container well using ( 2.2 ) .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": null,
    "adverseReactions": "history hypersensitivity megestrol acetate component formulation . pregnancy [ ( 5.2 ) , ( 8.1 , 8.3 ) ] .",
    "indications_original": "Megestrol acetate oral suspension is indicated for the treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS).\n                  \n                     Limitations of Use\n                  \n                  Therapy with megestrol acetate oral suspension for weight loss should only be insti\u00adtuted after treatable causes of weight loss are sought and addressed. These treatable causes include possible malignancies, systemic infections, gastrointestinal disorders affecting absorption, endocrine disease, renal disease or psychiatric diseases.\n                  Megestrol acetate oral suspension is not intended for prophylactic use to avoid weight loss.",
    "contraindications_original": "Obtain a negative pregnancy test in females of reproductive potential prior to initiating treatment ( 2.1 ) The recommended adult initial dosage of megestrol acetate oral suspension is 625 mg/day (5 mL/day or one teaspoon daily) ( 2.2 ). Shake container well before using ( 2.2 ).",
    "adverseReactions_original": "History of hypersensitivity to megestrol acetate or any component of the formulation.\n                     Pregnancy [see Warnings and Precautions (5.2), Use in Specific Populations (8.1, 8.3)].",
    "drug": [
        {
            "name": "Megestrol Acetate",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_6723"
        }
    ]
}